<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236921</url>
  </required_header>
  <id_info>
    <org_study_id>190051</org_study_id>
    <nct_id>NCT04236921</nct_id>
  </id_info>
  <brief_title>Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Bioequivalence Between DopaSnap® (Carbidopa/Levodopa 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet and to Evaluate the Food-Effect of DopaSnap® in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riverside Pharmacueticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riverside Pharmacueticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center, bioequivalence and food-effect, open-label study designed to be
      conducted in three sequential parts:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single center, bioequivalence and food-effect, open-label study designed to be
      conducted in three sequential parts:

        -  Part I: bioequivalence, food-effect, randomized, open-label, single dose, 3-period,
           6-sequence, crossover design.

        -  Part II: multiple-dose (every 4 hours), open-label, 1-period design.

        -  Part III: multiple-dose (every 2 hours), open-label, 1-period design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part I: bioequivalence, food-effect, randomized, open-label, single-dose, 3-period, 6-sequence, crossover design.
Part II: multiple-dose (every 4 hours), open-label, 1-period design.
Part III: multiple-dose (every 2 hours), open-label, 1-period design. Subjects enrolled in Part II and Part III will be a subset of those who completed Part I.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Residual area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. T½ el</description>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the rate and extent of absorption</measure>
    <time_frame>pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</time_frame>
    <description>• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Kel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food on the pharmacokinetics (PK)</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>PK Parameters: Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of a fraction of the DopaSnap® tablet</measure>
    <time_frame>A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.</time_frame>
    <description>• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Cmax</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Other</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x DopaSnap® tablet, administered under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x RLD of CD-LD tablet administered under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test - fed 1 x DopaSnap® tablet , administered under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DopaSnap®</intervention_name>
    <description>immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <other_name>test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDL of CD-LD</intervention_name>
    <description>(immediate release CD/LD 25/100mg; Merck Sharp &amp; Dohme Corp., USA),</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months
             prior to screening), ≥35 and ≤75 years of age, with BMI &gt; 18.5 and &lt; 30.0 kg/m2 and
             body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.

          2. Healthy as defined by:

               1. the absence of clinically significant illness and surgery within 4 weeks prior to
                  dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated
                  for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the
                  Qualified Investigator.

               2. the absence of clinically significant history of neurological, endocrinal,
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,
                  gastrointestinal, renal, hepatic, and metabolic disease.

          3. Females of childbearing potential who are sexually active with a male partner must be
             willing to use one of the following acceptable contraceptive methods throughout the
             study and for 30 days after the last study drug administration:

               1. intra-uterine contraceptive device placed at least 4 weeks prior to study drug
                  administration;

               2. male condom with intravaginally applied spermicide starting at least 21 days
                  prior to study drug administration;

               3. hormonal contraceptives starting at least 4 weeks prior to study drug
                  administration and must agree to use the same hormonal contraceptive throughout
                  the study;

               4. sterile male partner (vasectomized since at least 6 months).

          4. Capable of consent.

        Exclusion Criteria:

          -  1) Any clinically significant abnormality at physical examination, clinically
             significant abnormal laboratory test results or positive test for hepatitis B,
             hepatitis C, or HIV found during medical screening.

             2) Positive urine drug screen, alcohol breath test, or urine cotinine test at
             screening.

             3) History of allergic reactions to carbidopa, levodopa, or other related drugs, or to
             any excipient in the formulation.

             4) Positive pregnancy test at screening. 5) Clinically significant ECG abnormalities
             or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg,
             diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or
             over 100 bpm) at screening.

             6) History of significant alcohol abuse within 1 year prior to screening or regular
             use of alcohol within 6 months prior to the screening visit (more than 14 units of
             alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).

             7) History of significant drug abuse within 1 year prior to screening or use of soft
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and
             amphetamine derivatives) within 1 year prior to screening.

             8) Participation in a clinical research study involving the administration of an
             investigational or marketed drug or device within 30 days prior to the first dosing,
             administration of a biological product in the context of a clinical research study
             within 90 days prior to the first dosing, or concomitant participation in an
             investigational study involving no drug or device administration.

             9) Use of medication other than topical drug products without significant systemic
             absorption and hormonal contraceptives:

               1. prescription medication within 14 days prior to the first dosing;

               2. over-the-counter products and natural health products (including herbal remedies,
                  homeopathic and traditional medicines, probiotics, food supplements such as
                  vitamins, minerals, amino acids, essential fatty acids, and protein supplements
                  used in sports) within 14 days prior to the first dosing, with the exception of
                  the occasional use of acetaminophen (up to 2 g daily);

               3. a depot injection or an implant of any drug within 3 months prior to the first
                  dosing (other than hormonal contraceptives);

               4. MAO inhibitors within 30 days prior to the first dosing; 10) Donation of plasma
                  within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn
                  at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL
                  within 56 days prior to the first dosing.

                  11) Hemoglobin &lt; 128 g/L (males) and &lt; 115 g/L (females) and hematocrit &lt; 0.36
                  L/L (males) and &lt; 0.32 L/L (females) at screening.

                  12) Any reason which, in the opinion of the Investigator, would prevent the
                  subject from participating in the study.

                  13) Breast-feeding subject. 14) History or presence of myasthenia gravis. 15)
                  Treatment with centrally active drugs or those affecting peripheral cholinergic
                  transmission within 3 months of screening.

                  16) The presence of history of narrow angle glaucoma. 17) The presence of history
                  of depression, suicidal tendencies, and other psychotic disorders.

                  18) The presence of history of myocardial infarction, arrhythmias, bronchial
                  asthma and other cardiovascular, or pulmonary disease.

                  19) The presence of history of melanoma and suspicious undiagnosed skin lesions.

                  20) The presence of history of neuroleptic malignant syndrome and non-traumatic
                  rhabdomyolysis.

                  21) The presence of history of peptic ulcer disease or undiagnosed recurrent
                  gastro-intestinal bleeding.

                  22) The presence of history of convulsions. 23) HAMD-7 score above 3 at
                  screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Lamouche, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syneous Health</name>
      <address>
        <city>Québec</city>
        <state>Montreal</state>
        <zip>H3x 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

